Our expertise
At RedRidge Bio, we are leaders in the identification and development of biparatopic antibodies, designed to deliver exceptional efficacy across a range of disease areas, including oncology and autoimmunity.
With our integrated East–West operating model, we combine Swiss quality, designed and directed in Basel, with Chinese efficiency, executed at speed in Shanghai.
THE SCIENCE
Biparatopic binding of an antibody
Biparatopic binding of antibodies, meaning the targeting of two sites on a single protein, is a unique approach that enhances or introduces new properties, such as superior functional inhibition, efficient internalization for antibody-drug conjugates (ADCs), and fit-for-purpose agonism.
Combined with their high affinity and low-burden engineering, biparatopic antibodies (BPA) represent a promising, best-in-class therapeutic option for diverse diseases.
“RedRidge was born out of a vision for making combinatorial adjustments to the bellwether monoclonal antibody drug class, leading to therapeutics having a transformative patient benefit."
- Bill Sellers
Scientific founder
OUR FOCUS
Building therapies for oncology and autoimmunity
RedRidge is developing a suite of BPAs as therapies for cancer and autoimmune disease with higher efficacy and long-term safety.
Our translational experts in both fields align target and epitope selection, BPA discovery and engineering with disease biology and patient need to create the best therapies for a given indication.
Oncology
In oncology, our lead assets are biparatopic antibody drug conjugates for liquid and solid tumors.
Leveraging efficient internalization and equipped with disease-matched linker/payload combinations, they are designed to become effective treatments, even with very low target expression.
Autoimmune diseases
To deliver superior therapies in inflammatory and autoimmune diseases, the company is focusing on tissue-tethered immune cell modulators that suppress pathogenic immune responses, effectively resolving pathological inflammation.
TECHNOLOGY
Powerful use of new technologies
We use a systematic approach to identify BPAs, leveraging a deep understanding of target epitopes from both structural and disease biology perspectives.
Powered by high-throughput technologies and big data, we engineer, screen, and select BPAs tailored to meet specific therapeutic needs.
ABOUT US
We build,
innovate and
collaborate
We are a passionate, diverse team of scientists and professionals, united by a commitment to scientific excellence and innovation. Drawing from a range of backgrounds and nationalities, we foster an environment where deep science and fresh perspectives thrive.
We are driven by the goal of advancing BPA-based therapies that provide real, tangible value to patients.
Our collaborative spirit and cutting-edge research, combined with the expertise of our strategic alliances, enable us to tackle some of the most challenging issues in oncology, autoimmunity, and beyond.
Stephen Yoder
CEO
Rong Yang
COO
Florian Witte
Alliances & Project Management
Diana Graus Porta
Research
Francesca Amicarella
Translational Immunology
Mohammed Ullah
Developmental Sciences
Qiansheng Ren
Protein Engineering
Alex Mayweg
Managing director, Versant Ventures
Bill Sellers
Founder and Director Cancer Program, Broad Institute
Markus Warmuth
CEO, Monte Rosa
Ali Behbahani
Partner & Co-Head of Healthcare, NEA
Get in touch
We believe in the potential to unlock value through alliances and are actively seeking potential partners to join us in this endeavor.